AU2001243243A1 - Oxazolidinone tablet formulation - Google Patents
Oxazolidinone tablet formulationInfo
- Publication number
- AU2001243243A1 AU2001243243A1 AU2001243243A AU2001243243A AU2001243243A1 AU 2001243243 A1 AU2001243243 A1 AU 2001243243A1 AU 2001243243 A AU2001243243 A AU 2001243243A AU 2001243243 A AU2001243243 A AU 2001243243A AU 2001243243 A1 AU2001243243 A1 AU 2001243243A1
- Authority
- AU
- Australia
- Prior art keywords
- linezolid
- hydroxypropylcellulose
- compressed tablet
- microcrystalline cellulose
- magnesium stearate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
OXAZOLIDINONE TABLET FORMULATION CROSS-REFERENCE TO RELATED APPLICATIONS
None.
BACKGROUND OF THE INVENTION 1. Field of the Invention
The present invention is a novel tablet formulation which permits high drug load and does not use lactose.
2. Description of the Related Art Oxazolidinones are well known to those skilled in the art as gram positive anti-bacterial agents, see, for example, US Patents 5,688,792, 5,529,998, 5,547,950, 5,627,181, 5,700,799, 5,843,967, 5,792,765, 5,684,023, 5,861,413, 5,827,857, 5,869,659, 5,698,574, 5,968,962 and 5,981,528.
Various tablet formulations are very well known to those skilled in the art which contain starch, microcrystalline cellulose, hydroxypropylcellulose and other ingredients. However, it is very difficult to get high drug load and blood levels similar to IN administration.
SUMMARY OF INVENTION Disclosed is a compressed tablet containing the following ingredients: antibacterial oxazolidinone, starch, microcrystalline cellulose, binder selected from the group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose, povidone and corn starch paste, disintegrants selected from the group consisting of sodium starch glycolate, crosscarmellose sodium, crospovidone and low substituted hydroxypropylcellulose and lubricant selected from the group consisting of stearic acid, metalic salts of stearic acid, hydrogenated vegetable oil and talc.
Also disclosed is a method for providing blood levels of an antibacterial oxazolidinone by oral administration medically equivalent to the blood levels produced by IV administration of the same antibacterial oxazolidinone which comprises administration of a compressed tablet of the formulation: antibacterial oxazolidinone,
- l -
starch, microcrystalline cellulose, binder selected from the group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose, povidone and corn starch paste, hydroxypropylcellulose, disintegrants selected from the group consisting of sodium starch glycolate, crosscarmellose sodium, crospovidone and low substituted hydroxypropylcellulose and lubricant selected from the group consisting of stearic acid, metalic salts of stearic acid, hydrogenated vegetable oil and talc.
DETAILED DESCRIPTION OF THE INVENTION Oxazolidinones are a new class of gram positive antibacterial agents which are known to those skilled in the art, see for example US 5,688,792. (S)-N-[[3-[3-fluoro- 4-(4-mo holinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, known as linezolid, the compound of Example 5 of US Patent 5,688,792 is known and has the following chemical structural formula:
(S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-l-piperazinyl]-phenyl]-2-oxo-5- oxazolidinyl] methyl] acetamide, known as eperezolid, the compound of Example 8 of US Patent 5,837,870 is known and has the following chemical structural formula:
(S)-N-[[3-[3-fluoro-4-(tetrahydro-2H-thiopyran-4-yl)phenyl]-2-oxo-5- oxazolidinyl]methyl]acetamide S,S-dioxide the compound of Example 51 of US Patent 5,968,962 has the following chemical structural formula:
Linezolid and eperezolid can be produced by the processes set forth in US Patents 5,688,791 and 5,837,870 as well as that of International Publication WO99/24393. They are preferably produced by the process of US Patent 5,837,870. (S)-N-[[3-[3-fluoro-4-(tetrahydro-2H-thiopyran-4-yl)ρhenyl]-2-oxo-5- oxazolidinyl]methyl]acetamide S,S-dioxide can be produced by the process of US Patent 5,968,962 or the process of US Patent application Serial No. 60/118,150; it is preferred that it be produced by the process of US Patent application Serial No. 60/118,150.
When the antibacterial oxazolidinone is linezolid, it is preferred that linezolid produced be used in crystal form π, which has the characteristics set forth in CHART A. Once linezolid is synthesized, crystal Form π is prepared by starting with linezolid of high enantiomeric purity. It is preferred that the linezolid be more than 98% enantiomerically pure, it is more preferred that the linezolid be more than 99% pure and it is even more preferred that the linezolid be 99.5% pure. The linezolid of greater than 98% enantiomeric purity to be used to form crystal form II can either be in solution or be a solid. The linezolid starting material, solid or solution, is mixed with a solvent selected from the group consisting of compounds of the formula: water, acetonitrile, chloroform, methylene chloride, Rj-OH where Ri is C C6 alkyl; Ri-CO- R2 where R2 is Cι-C6 alkyl and Ri is as defined above; phenyl substituted with 1 thru 3 Ri where R\ is as defined above; Rι-CO-O-R2 where Ri is CpCβ alkyl and Ri is as defined above; R]-O-R2 where Ri is -Cό alkyl and Ri. is as defined above. It is preferred that the solvent be selected from the group consisting of water, ethyl acetate, methanol, ethanol, propanol, isopropanol, butanol, acetonitrile, acetone, methyl ethyl ketone, chloroform, methylene chloride, toluene, xylene, diethyl ether, or methyl-t- butyl ether. It is more preferred that the solvent be ethyl acetate, acetone, acetonitrile, propanol, or isopropanol. It is most preferred that the solvent be ethyl acetate. The mixture of linezolid in the solvent is agitated at a temperature below 80° until crystals
of Form II are formed and crystals of other solid forms, such as Form I, disappear. It is preferred to dissolve the linezolid in ethyl acetate at a temperature near the boiling point of the solvent. This mixture is cooled to a temperature of about 70°. The mixture may be seeded with crystals of Form II to facilitate crystallization. It is preferred that the solid product is cooled and agitated at a temperature between about 45° and about 60° until the solids consist only of Form LT crystals. It is most preferred to maintain the slurry at a temperature of about 55°. It is preferred to mix the linezolid and solvent for at least 10 min, it is even more preferred to mix the linezolid and solvent for at least 20 min and it is most preferred to mix the linezolid and solvent for at least 30 min. The time and temperature will vary depending on the solvent selected. With ethyl acetate it is preferred to mix for not less that 60 minutes. The crystalline slurry may be further cooled to improve yield, and the solid Form II product may be isolated. The mixture may be further cooled and agitated. Other measures which can be used to facilitate crystallization include, but are not limited to, cooling, concentration of the solution by evaporation or distillation, or through addition of other solvents. The crystals are isolated by procedures known to those skilled in the art.
The preferred solid oral dosage form is a tablet. The composition of the tablets of the present invention can vary but includes the following essential features: antibacterial oxazolidinone, starch, microcrystalline cellulose, binder selected from the group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose, povidone and corn starch paste, disintegrants selected from the group consisting of sodium starch glycolate, crosscarmellose sodium, crospovidone and low substituted hydroxypropylcellulose and lubricant selected from the group consisting of stearic acid, metalic salts of stearic acid, hydrogenated vegetable oil and talc. It is preferred that the antibacterial oxazolidinone is selected from the group consisting of linezolid, eperezolid and (S)-N-[[3-[3-fluoro-4-(tetrahydro-2H- thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide S,S-dioxide. It is more preferred that the antibacterial oxazolidinone is linezolid. It is preferred that the
linezolid is in crystal form π. It is preferred that the starch is corn starch. It is preferred that the binder is hydroxypropylcellulose and that the disintegrant is sodium starch glycolate. It is preferred that the lubricant is magnesium sterarte. It is preferred that the tablet is film coated. It is also preferred that the tablet has a hardness range is from about 18 to about 30 Strong Cobb units; it is more preferred that the tablet has a hardness range is from about 20 to about 25 Strong Cobb units.
When the antibacterial agent is linezolid it is preferred that the linezolid be present in 400 mg or 600 mg amounts; more preferably 600 mg. When linezolid is present in 400 mg, a preferred formulation is: Linezolid 400.0 mg
Corn starch 36.0-44.0 mg
Microcrystalline cellulose (intragranular) 14.4-17.6 mg
Hydroxypropylcellulose (intragranular) 5.32 - 6.52 mg
Hydroxypropylcellulose (binder solution) 1.9- 2.3 mg Microcrystalline cellulose (extragranular) 56.1-68.6 mg
Sodium starch glycolate 25.2-30.8 mg
Magnesium stearate 5.04-6.16 mg
It is more preferred that the 400 mg tablet be coated and have the following formulation: Linezolid 400.0 mg
Corn starch 36.0-44.0 mg
Microcrystalline cellulose (intragranular) 14.4-17.6 mg
Hydroxypropylcellulose (intragranular) 5.32 - 6.52 mg
Hydroxypropylcellulose (binder solution) 1.9- 2.3 mg Microcrystalline cellulose (extragranular) 56.1-68.6 mg
Sodium starch glycolate 25.2-30.8 mg
Magnesium stearate 5.04-6.16 mg
Opadry White YS-1-18202-A 11.2-22.4 mg
Carnaba Wax 0-0.224 mg It is even more preferred that the 400 mg tablet formulation be:
Linezolid 400.0 mg
Corn starch 40.0 mg
Microcrystalline cellulose (intragranular) 16.0 mg
Hydroxypropylcellulose (intragranular) 5.92 mg
Hydroxypropylcellulose (binder solution) 2.08 mg
Microcrystalline cellulose (extragranular) 62.4 mg
Sodium starch glycolate 28.0 mg Magnesium stearate 5.6 mg
It is most preferred that the 400 mg linezolid tablet formulation above be coated:
Linezolid 400.0 mg
Corn starch 40.0 mg
Microcrystalline cellulose (intragranular) 16.0 mg Hydroxypropylcellulose (intragranular) 5.92 mg
Hydroxypropylcellulose (binder solution) 2.08 mg
Microcrystalline cellulose (extragranular) 62.4 mg
Sodium starch glycolate 28.0 mg
Magnesium stearate 5.6 mg Opadry White YS-1- 18202- A 16.8 mg
Carnaba Wax 0.224 mg When linezolid it present in 600 mg, a preferred tablet formulation is:
Linezolid 600.0 mg
Corn starch 54-66 mg Microcrystalline cellulose (intragranular) 21.6-26.4 mg
Hydroxypropylcellulose (intragranular) 7.98-9.78 mg
Hydroxypropylcellulose (binder solution) 2.82-3.42 mg
Microcrystalline cellulose (extragranular) 84.24-102.96 mg
Sodium starch glycolate 37.8-46.2 mg Magnesium stearate 7.56-9.24 mg It is more preferred that the 600 mg linezolid tablet formulation be coated:
Linezolid 600.0 mg
Corn starch 54-66 mg
Microcrystalline cellulose (intragranular) 21.6-26.4 mg Hydroxypropylcellulose (intragranular) 7.98-9.78 mg
Hydroxypropylcellulose (binder solution) 2.82-3.42 mg
Microcrystalline cellulose (extragranular) 84.24-102.96 mg
Sodium starch glycolate 37.8-46.2 mg
Magnesium stearate 7.56-9.24 mg
Opadry White YS-1-18202-A 16.8-33.6 mg
Carnaba Wax 0-0.336 mg
It is also preferred that the 600 mg linezolid tablet formulation be: Linezolid 600.0 mg
Corn starch 60.0 mg
Microcrystalline cellulose (intragranular) 24.0 mg
Hydroxypropylcellulose (intragranular) 8.88 mg
Hydroxypropylcellulose (binder solution) 3.12 mg Microcrystalline cellulose (extragranular) 93.6 mg
Sodium starch glycolate 42.0 mg
Magnesium stearate 8.4 mg
It is most preferred that the 600 mg linezolid tablet be coated:
Linezolid 600.0 mg Corn starch 60.0 mg
Microcrystalline cellulose (intragranular) 24.0 mg
Hydroxypropylcellulose (intragranular) 8.88 mg
Hydroxypropylcellulose (binder solution) 3.12 mg
Microcrystalline cellulose (extragranular) 93.6 mg Sodium starch glycolate 42.0 mg
Magnesium stearate 8.4 mg
Opadry White YS-1-18202-A 25.2 mg
Carnaba Wax 0.0336 mg
The above tablet formulations are prepared by methods well known to those skilled in the art. It is preferred that the tablet formulations of the present invention be prepared as follows. The binder solution is prepared by adding part of the hydroxypropylcellulose to the purified water and mixing in an appropriate container until dissolved. The granulation is performed by adding the antibacterial oxazolidinone, corn starch, microcrystalline cellulose (intragranular, 24.0 mg), and the remaining hydroxypropylcellulose into a high shear mixer and mixing until adequately mixed. Then add the binder solution while mixing, and if needed, add an additional sufficient quantity of water while mixing, to form the granulation. Wet screen the granulation using appropriate equipment as is well known to those skilled in the art,
for example, a Comil. Following granulation the granulation is dried using suitable equipment, such as a fluid bed dryer. After the granulation is dried, dry screen the granulation using appropriate equipment, such as a Comil. The lubrication portion is formed by mixing microcrystalline cellulose (extragranular, 93.6 mg) and sodium starch glycolate with the dry screened granulation in a suitable blender, such as a diffusion (tumble) type V-blender, until adequately blended. Next remove a portion of the blended material and combine with the magnesium stearate. Add the magnesium stearate mixture back into the blender, such as a diffusion (tumble) type V-blender, and mix until adequately blended. Finally, collect the lubricated powder mixture in appropriate containers.
Alternatively, no binder solution need be used. All the hydroxypropylcellulose can be added as powder. In that situation, the antibacterial oxazolidinone, starch and microcrystalline cellulose and hydroxypropylcellulose are combined, mixed and then the water is added. It is preferred that a binder solution be used. The compressed tablets are formed using a suitable rotary compresion machine and compression tooling. The lubricated powder mixture is compressed into tablets of proper weight, hardness, size and shape.
It is preferred to coat and wax the tablets. The Opadry White YS-1-18202-A and purified water are mixed to prepare the coating suspension. The coating mixture should be continuously stirred until the mixture is free of lumps and the Opadry is in suspension. Prior to using, the film coating suspension should be screened through an appropriate screen. The desired quantity of tablets is loaded into the appropriately sized perforated coating pans (such as an Accela-Cota or Glatt coating pan) equipped with baffles, spray guns and pumping system. The appropriate amount of aqueous film coating is sprayed on the moving tablets until tablets are evenly coated. After the coating is complete, the appropriate amount of carnauba wax is weighed and added to the bed of tablets to polish the film coated tablets.
It is preferred to print the tablets with identifying information as is known to those skilled in the art. A flow chart of the manufacturing process is provided in CHART B.
The present invention also includes a method for providing blood levels of an antibacterial oxazolidinone by oral administration medically equivalent to the blood
levels produced by IV administration of the same antibacterial oxazolidinone which comprises administration of a compressed tablet of the formulation: antibacterial oxazolidinone, starch, microcrystalline cellulose, binder selected from the group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose, povidone and corn starch paste, disintegrants selected from the group consisting of sodium starch glycolate, crosscarmellose sodium, crospovidone and low substituted hydroxypropylcellulose and lubricant selected from the group consisting of stearic acid, metalic salts of stearic acid, hydrogenated vegetable oil and talc. All the preferences above with regard to the tablet formulation/composition are preferences for the method of providing blood levels of an antibacterial oxazolidinone by oral administration medically equivalent to the blood levels produced by IV administration of the same antibacterial oxazolidinone.
It is well known to those skilled in the art how to use the oxazolidinone tablets of the present invention. See for example, US Patents 5,688,792, 5,547,950 and
5,968,962. DEFINITIONS AND CONVENTIONS
The definitions and explanations below are for the terms as used throughout this entire document including both the specification and the claims.
DEFINITIONS
Linezolid refers to (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]acetamide is the compound of formula:
Eperezolid refers to (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-l-piperazinyl]- phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide is the compound of formula:
All temperatures are in degrees Celsius. USP refers to the United States Pharmacopiea. NF refers to the National Formulary.
Pharmaceutically acceptable refers to those properties and/or substances which are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability. When solvent pairs are used, the ratios of solvents used are volume/volume
(v/v).
When the solubility of a solid in a solvent is used the ratio of the solid to the solvent is weight/volume (wt/v).
Opadry White refers to Colorcon's tablet coating product. The product code YS - 1 - 18202- A refers to a specific tablet coating formula.
EXAMPLES Without further elaboration, it is believed that one skilled in the art can, using the preceding description, practice the present invention to its fullest extent. The following detailed examples describe how to prepare the various compounds and/or perform the various processes of the invention and are to be construed as merely illustrative, and not limitations of the preceding disclosure in any way whatsoever. Those skilled in the art will promptly recognize appropriate variations from the procedures both as to reactants and as to reaction conditions and techniques. EXAMPLE 1 Linezolid (400 mg) Tablet Formulation Ingredients Amount
Linezolid 400.0 mg
Corn starch NF 40.0 mg
Microcrystalline cellulose NF 16.0 mg
Hydroxypropylcellulose (intragranular) NF 5.92 mg
Hydroxypropylcellulose (binder solution) NF 2.08 mg
Microcrystalline cellulose NF 62.4 mg Sodium starch glycolate NF 28.0 mg
Magnesium stearate NF 5.6 mg
Purified water USP 22.0% uncoated tablet wt Film Coating Phase
Opadry White YS-1-18202-A 16.8 mg Purified Water USP 129.2 mg
Polishing Phase
Carnauba Wax NF 0.0224 mg
The binder solution is prepared by adding part of the hydroxypropylcellulose to the purified water and mixing in an appropriate container until dissolved. The granulation is performed by adding the antibacterial oxazolidinone, corn starch, microcrystalline cellulose (intragranular, 24.0 mg), and the remaining hydroxypropylcellulose into a high shear mixer and mixing until adequately mixed. Then add the binder solution while mixing, and if needed, add an additional sufficient quantity of water while mixing, to form the granulation. Wet screen the granulation using appropriate equipment as is well known to those skilled in the art, for example, a Comil. Following granulation the granulation is dried using suitable equipment, such as a fluid bed dryer. After the granulation is dried, dry screen the granulation using appropriate equipment, such as a Comil. The lubrication portion is formed by mixing microcrystalline cellulose (extragranular, 93.6 mg) and sodium starch glycolate with the dry screened granulation in a suitable blender, such as a diffusion (tumble) type V-blender, until adequately blended. Next remove a portion of the blended material and combine with the magnesium stearate. Add the magnesium stearate mixture back into the blender, such as a diffusion (tumble) type V-blender, and mix until adequately blended. Finally, collect the lubricated powder mixture in appropriate containers.
The compressed tablets are formed using a suitable rotary compression machine and compression tooling. The lubricated powder mixture is compressed into tablets of proper weight, hardness, size and shape.
It is preferred to coat and wax the tablets. The Opadry White YS-1-18202-A and purified water are mixed to prepare the coating suspension. The coating mixture should be continuously stirred until the mixture is free of lumps and the Opadry is in suspension. Prior to using, the film coating suspension should be screened through an appropriate screen. The desired quantity of tablets is loaded into the appropriately sized perforated coating pans (such as an Accela-Cota or Glatt coating pan) equipped with baffles, spray guns and pumping system. The appropriate amount of aqueous film coating is sprayed on the moving tablets until tablets are evenly coated. After the coating is complete, the appropriate amount of carnauba wax is weighed and added to the bed of tablets to polish the film coated tablets.
It is preferred to print the tablets with identifying information as is known to those skilled in the art.
A flow chart of the manufacturing process is provided in CHART B. EXAMPLE 2 Linezolid (600 mg) Tablet Formulation Ingredients Amount
Linezolid 600.0 mg
Corn starch NF 60.0 mg
Microcrystalline cellulose NF 24.0 mg
Hydroxypropylcellulose (intragranular) NF 8.88 mg Hydroxypropylcellulose (binder solution) NF 3.12 mg
Microcrystalline cellulose NF 93.6 mg
Sodium starch glycolate NF 42.0 mg
Magnesium stearate NF 8.4 mg
Purified water USP 22.0% uncoated tablet wt Film Coating Phase
Opadry White YS-1-18202-A 25.2 mg
Purified Water USP 193.9 mg
Polishing Phase
Carnauba Wax NF 0.0336 mg Following the general procedure of EXAMPLE 1 and making non-critical variations but using the amounts of ingredients above Linezolid 600 mg tablets are produced.
CHART A
Linezolid, (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5- oxazolidinyl]methyl]acetamide, crystal "Form II" has the powder X-ray diffraction spectrum of: d-Spacing (A) Two-Theta Angle (°) Relative Intensity (%)
12.44 7.10 2
9.26 9.54 9
6.37 13.88 6
6.22 14.23 24
5.48 16.18 3
5.28 16.79 100
5.01 17.69 2
4.57 19.41 4
4.50 19.69 2
4.45 19.93 6
4.11 21.61 15
3.97 22.39 23
3.89 22.84 4
3.78 23.52 7
3.68 24.16 1
3.52 25.28 13
3.34 26.66 1
3.30 27.01 3
3.21 27.77 1 and an infrared (IR) spectrum (mineral oil mull) of 3364, 1748, 1675, 1537, 1517, 1445, 1410, 1401, 1358, 1329, 1287, 1274, 1253, 1237, 1221, 1145, 1130, 1123, 1116, 1078, 1066, 1049, 907, 852 and 758 cm"1.
CHART B
Linezolid Tablet Manufacturing Flowchart
Weigh ingredients
I
Prepare granulating fluid i
Pre-blend specified ingredients using a high-shear mixer i
Granulate using the high shear mixer i
Pass the wet granules through a screening device i
Dry using a fluid bed dryer i
Screen granules using a screening device i
Blend with specified remaining ingredients using a diffusion (tumble) type V-blender
I
Combine magnesium stearate with a portion of the blended materials i
Add the magnesium stearate mixture to the blender and lubricate i
Compress into tablets using rotary tablet machines and appropriate tooling i
Prepare coating suspension
Coat tablets using coating pans
I
Polish tablets with carnauba wax using coating pans
I
Package tablets
Claims (30)
1. A compressed tablet containing the following ingredients: antibacterial oxazolidinone, starch, microcrystalline cellulose, binder selected from the group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose, povidone and corn starch paste, disintegrants selected from the group consisting of sodium starch glycolate, crosscarmellose sodium, crospovidone and low substituted hydroxypropylcellulose and lubricant selected from the group consisting of stearic acid, metalic salts of stearic acid, hydrogenated vegetable oil and talc.
2. A compressed tablet according to claim 1 where the antibacterial oxazolidinone is selected from the group consisting of linezolid, eperezolid and (S)-N-[[3-[3-fluoro-4-
(tetrahydro-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide S,S- dioxide.
3. A compressed tablet according to claim 2 where the antibacterial oxazolidinone is linezolid.
4. A compressed tablet according to claim 3 where the linezolid is in crystal form π.
5. A compressed tablet according to claim 1 where the starch is corn starch.
6. A compressed tablet according to claim 1 where the binder is hydroxypropylcellulose.
7. A compressed tablet according to claim 1 where the disintegrant is sodium starch glycolate.
8. A compressed tablet according to claim 1 where the lubricant is magnesium sterarte.
9. A compressed tablet according to claim 1 where the tablet is film coated.
10. A compressed tablet according to claim 1 where the tablet has a hardness range is from about 18 to about 30 Strong Cobb units.
11. A compressed tablet according to claim 10 where the tablet has a hardness range is from about 20 to about 25 Strong Cobb units.
12. A compressed tablet according to claim 1 which contains:
Linezolid 400.0 mg
Corn starch 36.0-44.0 mg
Microcrystalline cellulose 70.5-86.2 mg
Hydroxypropylcellulose 7.2-8.8 mg Sodium starch glycolate 25.2-30.8 mg
Magnesium stearate 5.04-6.16 mg
13. A compressed tablet according to claim 12 which contains:
Linezolid 400.0 mg Corn starch 36.0-44.0 mg
Microcrystalline cellulose 70.5-86.2 mg
Hydroxypropylcellulose 7.2-8.8 mg
Sodium starch glycolate 25.2-30.8 mg
Magnesium stearate 5.04-6.16 mg Opadry White YS- 1 - 18202-A 11.2-22.4 mg
Carnaba Wax 0-0.0224 mg
14. A compressed tablet according to claim 12 which contains:
Linezolid 400.0 mg Corn starch 40.0 mg
Microcrystalline cellulose 78.4 mg
Hydroxypropylcellulose 8.00 mg
Sodium starch glycolate 28.0 mg Magnesium stearate 5.6 mg
15. A compressed tablet according to claim 14 which contains:
Linezolid 400.0 mg Corn starch 40.0 mg
Microcrystalline cellulose 78.4 mg
Hydroxypropylcellulose 8.00 mg
Sodium starch glycolate 28.0 mg
Magnesium stearate 5.6 mg Opadry White YS- 1-18202-A 16.8 mg
Carnaba Wax 0.0224 mg
16. A compressed tablet according to claim 1 which contains:
Linezolid 600.0 mg Corn starch 54-66 mg
Microcrystalline cellulose 105.84-129.36 mg
Hydroxypropylcellulose 10.8-13.2 mg
Sodium starch glycolate 37.8-46.2 mg
Magnesium stearate 7.56-9.24 mg
17. A compressed tablet according to claim 16 where:
Linezolid 600.0 mg
Corn starch 54-66 mg
Microcrystalline cellulose 105.84- 129.36 mg Hydroxypropylcellulose 10.8-13.2 mg
Sodium starch glycolate 37.8-46.2 mg
Magnesium stearate 7.56-9.24 mg
Opadry White YS-1-18202-A 16.8-33.6 mg
Carnaba Wax 0-0.0336 mg
18. A compressed tablet according to claim 16 where:
Linezolid 600.0 mg
Corn starch 60.0 mg Microcrystalline cellulose 117.6 mg
Hydroxypropylcellulose 12.00 mg
Sodium starch glycolate 42.0 mg
Magnesium stearate 8.4 mg
19. A compressed tablet according to claim 18 where:
Linezolid 600.0 mg
Corn starch 60.0 mg
Microcrystalline cellulose 1 17.6 mg Hydroxypropylcellulose 12.00 mg
Sodium starch glycolate 42.0 mg
Magnesium stearate 8.4 mg
Opadry White YS-1-18202-A 25.2 mg
Carnaba Wax 0.0336 mg
20. A method for providing blood levels of an antibacterial oxazolidinone by oral administration medically equivalent to the blood levels produced by TV administration of the same antibacterial oxazolidinone which comprises administration of a compressed tablet of the formulation: antibacterial oxazolidinone, starch, microcrystalline cellulose, binder selected from the group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose, povidone and corn starch paste, hydroxypropylcellulose, disintegrants selected from the group consisting of sodium starch glycolate, crosscarmellose sodium, crospovidone and low substituted hydroxypropylcellulose and lubricant selected from the group consisting of stearic acid, metalic salts of stearic acid, hydrogenated vegetable oil and talc.
21. A method according to claim 20 where the antibacterial oxazolidinone is selected from the group consisting of linezolid, eperezolid and (S)-N-[[3-[3-fluoro-4- (tetrahydro-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide S,S- dioxide.
22. A compressed tablet according to claim 21 where the antibacterial oxazolidinone is selected from the group consisting of linezolid.
23. A method according to claim 22 where the compressed tablet contains: Linezolid 400.0 mg
Corn starch 36.0-44.0 mg Microcrystalline cellulose 70.5-86.2 mg
Hydroxypropylcellulose 7.2-8.8 mg
Sodium starch glycolate 25.2-30.8 mg
Magnesium stearate 5.04-6.16 mg
24. A method according to claim 23 where the compressed tablet contains: Linezolid 400.0 mg
Corn starch 36.0-44.0 mg
Microcrystalline cellulose 70.5-86.2 mg Hydroxypropylcellulose 7.2-8.8 mg Sodium starch glycolate 25.2-30.8 mg
Magnesium stearate 5.04-6.16 mg
Opadry White YS-1-18202-A 11.2-22.4 mg
Carnaba Wax 0-0.0224 mg
25. A method according to claim 23 where the compressed tablet contains:
Linezolid 400.0 mg
Corn starch 40.0 mg
Microcrystalline cellulose 78.4 mg
Hydroxypropylcellulose 8.00 mg Sodium starch glycolate 28.0 mg
Magnesium stearate 5.6 mg
26. A method according to claim 25 where the compressed tablet contains: Linezolid 400.0 mg
Corn starch 40.0 mg
Microcrystalline cellulose 78.4 mg
Hydroxypropylcellulose 8.00 mg Sodium starch glycolate 28.0 mg
Magnesium stearate 5.6 mg
Opadry White YS-1-18202-A 16.8 mg
Carnaba Wax 0.0224 mg
27. A method according to claim 22 where the compressed tablet contains:
Linezolid 600.0 mg
Corn starch 54-66 mg
Microcrystalline cellulose 105.84-129.36 mg
Hydroxypropylcellulose 10.8-13.2 mg Sodium starch glycolate 37.8-46.2 mg
Magnesium stearate 7.56-9.24 mg
28. A method according to claim 27 where the compressed tablet contains:
Linezolid 600.0 mg Corn starch 54-66 mg
Microcrystalline cellulose 105.84-129.36 mg
Hydroxypropylcellulose 10.8-13.2 mg
Sodium starch glycolate 37.8-46.2 mg
Magnesium stearate 7.56-9.24 mg Opadry White YS-1-18202-A 16.8-33.6 mg
Carnaba Wax 0-0.0336 mg
29. A method according to claim 27 where the compressed tablet contains:
Linezolid 600.0 mg Corn starch 60.0 mg
Microcrystalline cellulose 117.6 mg
Hydroxypropylcellulose 12.00 mg
Sodium starch glycolate 42.0 mg Magnesium stearate 8.4 mg
30. A method according to claim 29 where the compressed tablet contains:
Linezolid 600.0 mg Corn starch 60.0 mg
Microcrystalline cellulose 117.6 mg
Hydroxypropylcellulose 12.00 mg
Sodium starch glycolate 42.0 mg
Magnesium stearate 8.4 mg Opadry White YS-1-18202-A 25.2 mg
Carnaba Wax 0.0336 mg
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19096900P | 2000-03-22 | 2000-03-22 | |
| US60/190,969 | 2000-03-22 | ||
| PCT/US2001/005812 WO2001070225A2 (en) | 2000-03-22 | 2001-03-15 | Oxazolidinone tablet formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2001243243A1 true AU2001243243A1 (en) | 2001-12-13 |
| AU2001243243B2 AU2001243243B2 (en) | 2004-10-14 |
Family
ID=22703542
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU4324301A Pending AU4324301A (en) | 2000-03-22 | 2001-03-15 | Oxazolidinone tablet formulation |
| AU2001243243A Ceased AU2001243243B2 (en) | 2000-03-22 | 2001-03-15 | Oxazolidinone tablet formulation |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU4324301A Pending AU4324301A (en) | 2000-03-22 | 2001-03-15 | Oxazolidinone tablet formulation |
Country Status (33)
| Country | Link |
|---|---|
| EP (1) | EP1265608B1 (en) |
| JP (1) | JP2003527424A (en) |
| KR (2) | KR20070094673A (en) |
| CN (1) | CN1208058C (en) |
| AR (1) | AR033357A1 (en) |
| AT (1) | ATE412413T1 (en) |
| AU (2) | AU4324301A (en) |
| BG (1) | BG107117A (en) |
| BR (1) | BR0108846A (en) |
| CA (1) | CA2400118A1 (en) |
| CZ (1) | CZ20023133A3 (en) |
| DE (1) | DE60136341D1 (en) |
| DK (1) | DK1265608T3 (en) |
| EA (1) | EA006772B1 (en) |
| EC (1) | ECSP013979A (en) |
| ES (1) | ES2312422T3 (en) |
| HK (1) | HK1054325B (en) |
| HR (1) | HRP20020765A2 (en) |
| HU (1) | HUP0300378A3 (en) |
| IL (1) | IL151788A0 (en) |
| MX (1) | MXPA02009316A (en) |
| MY (1) | MY136370A (en) |
| NO (1) | NO20024505L (en) |
| NZ (1) | NZ521525A (en) |
| PE (2) | PE20011126A1 (en) |
| PL (1) | PL201686B1 (en) |
| PT (1) | PT1265608E (en) |
| SK (1) | SK12092002A3 (en) |
| TW (1) | TWI293028B (en) |
| UA (1) | UA77654C2 (en) |
| WO (1) | WO2001070225A2 (en) |
| YU (1) | YU69802A (en) |
| ZA (1) | ZA200207073B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| ES2309920T3 (en) * | 2005-07-20 | 2008-12-16 | Teva Pharmaceutical Industries Ltd. | STABLE PHARMACEUTICAL COMPOSITION UNDERSTANDING LINEZOLID FORM III. |
| WO2010026597A1 (en) * | 2008-09-02 | 2010-03-11 | Hetero Research Foundation | Oral dosage forms of linezolid and processes for their preparation |
| ES2836809T3 (en) * | 2010-11-24 | 2021-06-28 | Melinta Subsidiary Corp | Pharmaceutical compositions |
| WO2013088389A1 (en) * | 2011-12-14 | 2013-06-20 | Alembic Pharmaceuticals Limited | Linezolid premix |
| CN103505459B (en) * | 2012-06-20 | 2016-02-24 | 北京万生药业有限责任公司 | Pharmaceutical composition of linezolid |
| CN104622831B (en) * | 2013-11-06 | 2018-06-22 | 江苏豪森药业集团有限公司 | A kind of oral tablet and preparation method thereof |
| BR112017021097B1 (en) | 2015-04-01 | 2024-01-02 | Akebia Therapeutics, Inc | ORAL DOSAGE FORMULATION AND ITS USE |
| CN106727396A (en) * | 2016-11-22 | 2017-05-31 | 湖北广济药业股份有限公司 | A kind of II crystal linezolid piece and preparation method thereof |
| CN109481412A (en) * | 2018-08-17 | 2019-03-19 | 扬子江药业集团北京海燕药业有限公司 | A kind of II crystal linezolid piece and its preparation process |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3993767A (en) * | 1975-11-18 | 1976-11-23 | A. H. Robins Company, Incorporated | Compositions to suppress gastric bleeding in indomethacin and phenylbutazone therapy |
| AUPP437698A0 (en) * | 1998-06-30 | 1998-07-23 | Baumgart, Karl | Methods for treatment of coronary, carotid and other vascular disease |
| AU767380B2 (en) * | 1999-05-27 | 2003-11-06 | Pharmacia & Upjohn Company | Bicyclic oxazolidinones as antibacterial agent |
-
2001
- 2001-03-15 DE DE60136341T patent/DE60136341D1/en not_active Expired - Fee Related
- 2001-03-15 MX MXPA02009316A patent/MXPA02009316A/en not_active Application Discontinuation
- 2001-03-15 DK DK01916186T patent/DK1265608T3/en active
- 2001-03-15 AU AU4324301A patent/AU4324301A/en active Pending
- 2001-03-15 EA EA200201006A patent/EA006772B1/en not_active IP Right Cessation
- 2001-03-15 CA CA002400118A patent/CA2400118A1/en not_active Abandoned
- 2001-03-15 ES ES01916186T patent/ES2312422T3/en not_active Expired - Lifetime
- 2001-03-15 HU HU0300378A patent/HUP0300378A3/en unknown
- 2001-03-15 IL IL15178801A patent/IL151788A0/en unknown
- 2001-03-15 AT AT01916186T patent/ATE412413T1/en not_active IP Right Cessation
- 2001-03-15 CN CNB018064698A patent/CN1208058C/en not_active Expired - Fee Related
- 2001-03-15 YU YU69802A patent/YU69802A/en unknown
- 2001-03-15 UA UA2002108322A patent/UA77654C2/en unknown
- 2001-03-15 AU AU2001243243A patent/AU2001243243B2/en not_active Ceased
- 2001-03-15 KR KR1020077020576A patent/KR20070094673A/en not_active Application Discontinuation
- 2001-03-15 NZ NZ521525A patent/NZ521525A/en unknown
- 2001-03-15 PL PL366067A patent/PL201686B1/en unknown
- 2001-03-15 PT PT01916186T patent/PT1265608E/en unknown
- 2001-03-15 SK SK1209-2002A patent/SK12092002A3/en unknown
- 2001-03-15 BR BR0108846-7A patent/BR0108846A/en not_active IP Right Cessation
- 2001-03-15 JP JP2001568423A patent/JP2003527424A/en not_active Ceased
- 2001-03-15 CZ CZ20023133A patent/CZ20023133A3/en unknown
- 2001-03-15 WO PCT/US2001/005812 patent/WO2001070225A2/en active IP Right Grant
- 2001-03-15 KR KR1020027012465A patent/KR100786410B1/en not_active IP Right Cessation
- 2001-03-15 EP EP01916186A patent/EP1265608B1/en not_active Revoked
- 2001-03-20 MY MYPI20011303A patent/MY136370A/en unknown
- 2001-03-22 PE PE2001000273A patent/PE20011126A1/en not_active Application Discontinuation
- 2001-03-22 AR ARP010101348A patent/AR033357A1/en unknown
- 2001-03-22 TW TW090106735A patent/TWI293028B/en active
- 2001-03-22 EC EC2001003979A patent/ECSP013979A/en unknown
- 2001-05-15 PE PE2001000437U patent/PE20020499Z/en not_active IP Right Cessation
-
2002
- 2002-09-03 ZA ZA200207073A patent/ZA200207073B/en unknown
- 2002-09-18 BG BG107117A patent/BG107117A/en unknown
- 2002-09-19 HR HR20020765A patent/HRP20020765A2/en not_active Application Discontinuation
- 2002-09-20 NO NO20024505A patent/NO20024505L/en not_active Application Discontinuation
-
2003
- 2003-09-11 HK HK03106507.0A patent/HK1054325B/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6514529B2 (en) | Oxazolidinone tablet formulation | |
| EP1749517B1 (en) | Stable pharmaceutical composition comprising linezolid form IV | |
| NO346639B1 (en) | Pharmaceutical preparations and method for their production | |
| AU2001243243B2 (en) | Oxazolidinone tablet formulation | |
| EP1266657A1 (en) | Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride | |
| AU2001243243A1 (en) | Oxazolidinone tablet formulation | |
| PH12014502538B1 (en) | Amorphous form of an akt inhibiting pyrimidinyl - cyclopentane compound, compositions and methods tehreof | |
| US20070219250A1 (en) | Pharmaceutical Compositions of Nateglinide | |
| NZ503413A (en) | Particle compositions of lipid lowering agents | |
| CA2633356C (en) | Pharmaceutical composition containing donepezil hydrochloride, tablets produced therefrom and method for producing the same | |
| WO2009140105A2 (en) | Formulations for cathepsin k inhibitors | |
| WO2007102082A1 (en) | High oxazolidinone content solid dosage forms | |
| WO2022003643A1 (en) | Stable solid formulation of azilsartan kamedoxomil, or azilsartan or pharmaceutically acceptable salts thereof | |
| WO2010125572A1 (en) | Compressed tablets and capsules containing efavirenz | |
| EP2611799A2 (en) | Pharmaceutical compositions of linezolid | |
| JP2002532429A (en) | Pharmaceutical formulations | |
| US20010046992A1 (en) | Treatment of urinary tract infections with antibacterial oxazolidinones | |
| EP1776102A1 (en) | Preparations of stable pharmaceutical compositions of nateglinide and processes for their preparation | |
| EP4260848A1 (en) | Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation | |
| RU2690491C2 (en) | Solid-phase linezolid-containing preparation | |
| JP2021116239A (en) | Dissolution-controlled dasatinib anhydride-containing pharmaceutical composition |